Climb Bio, INC. (CLYM) — 10-Q Filings

10-Q Filings (5)

• Climb Bio's Cash Dwindles Amid Soaring R&D Costs — Nov 6, 2025 Risk: high
  Climb Bio, Inc. (CLYM) reported a net loss of $12.888 million for the three months ended September 30, 2025, a significant increase from the $8.895 million net
• Climb Bio Narrows Loss to $29.4M Amid R&D Surge, Cash Dwindles — Aug 12, 2025 Risk: high
  Climb Bio, Inc. (CLYM) reported a net loss of $29.447 million for the six months ended June 30, 2025, a significant improvement from the $56.586 million net los
• Climb Bio, Inc. Files Q1 2025 10-Q — May 14, 2025 Risk: low
  Climb Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Eliem Therapeutics, Inc., reported on its financial status,
• Climb Bio, Inc. Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Climb Bio, Inc. filed a 10-Q for the period ending September 30, 2024. The company, formerly known as Eliem Therapeutics, Inc., reported on its financial activi
• Eliem Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: low
  Eliem Therapeutics, Inc. (CLYM) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Eliem Therapeutics, Inc. filed a 10-Q report for the quarterly per

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX